A merchant bank operates investment and advisory platforms while also being an active investor on a principal basis. The firm invests in a variety of industries including media & entertainment, renewable energy, digital assets, consumer, and life sciences. The firm recently had an initial close on their inaugural life sciences fund, and is actively seeking early-stage investment opportunities in Series A to C rounds. Initial check sizes will be between $3-7M with reserved follow-on investments. The firm focuses US-based companies, and will consider those based in Europe, Israel, and other geographies who are looking to expand operations or relocate to the US.
Within life sciences, the firm will consider opportunities in therapeutics, medical devices, and diagnostics. The firm does not invest in digital health or healthcare IT-based solutions. The firm is opportunistic and will consider all types of novel modalities, technologies, and disease areas that address a high unmet medical need. While the firm does invest in early-stage companies, the firm will expect companies to have a lead asset and indication in place, demonstrating strong pre-clinical data and be close to IND filing.
The firm seeks to work with companies with a committed, full-time management team in place. The firm typically does not lead investment rounds and prefers to syndicate with other likeminded investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment